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Genetic variants have long been suspected to be
important in psoriasis. Recent work has suggested
that HLA-Cw6 on chromosome 6 is the risk variant in
the PSORS1 [MIM 177900] susceptibility locus that
confers the greatest risk for early onset of psoriasis.
Although numerous minor susceptibility loci have
been identified by linkage analysis, few biologically
relevant candidates have been discovered within
these intervals. Recent large-scale genome-wide asso-
ciation studies have yielded new candidates in genes
encoding cytokines with functional relevance to
psoriasis. Polymorphisms within the genes encoding
the IL-12 p40 subunit, IL12B, and one of the IL-23
receptor subunits, IL23R, have been replicated in US
and European populations and overlap with risk of
Crohn’s disease. Polymorphisms within the gene
encoding IL-13, a Th2 cytokine, also confer risk for
psoriasis. Variants of the gene IL15 encoding IL-15
have been identified that associate with psoriasis in a
Chinese population. These discoveries pose the
challenge of elucidating the role of common genetic
variants in susceptibility to and manifestations of
psoriasis.
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PSORIASIS IS A COMPLEX POLYGENIC DISORDER
Psoriasis is a chronic inflammatory disorder that affects
0.6–4.8% of the population worldwide (Naldi, 2004).
Psoriasis has long been considered a disorder with a genetic
basis, supported by familial clustering of the disease
(Lomholt, 1976), increased concordance among monozygo-
tic twins (Brandrup et al., 1982) and the repeatedly confirmed
association with HLA-Cw6 (Nair et al., 2006). However, only
60–65% of individuals with psoriasis carry this risk variant,
and 15% of individuals without psoriasis carry HLA-Cw6
(Gudjonsson et al., 2006), lending support to the widely held
belief that other common genetic variants contribute to
psoriasis susceptibility. In the last decade, numerous genome-
wide scans using linkage analysis on multiply affected
families, have elucidated eight other replicated susceptibility
loci (PSORS2–9) as reviewed by Capon et al. (2004). Follow-
up sequencing and fine mapping within these susceptibility
loci have, to date, yielded few candidate genes with biologic
relevance to psoriasis pathophysiology.
A NEW ERA OF GENOME-WIDE ASSOCIATION
Genome-wide studies were initially performed using linkage
analysis, which relies on the concept that a marker allele near
a disease gene is coinherited with that disease gene within a
family unless a recombination event has occurred. Marker
alleles are then traced in families that have affected and
unaffected individuals. With the better understanding of
genomic variation of the human genome provided by the
International HapMap Consortium (2005), genome-wide
studies can now be performed by association rather than
linkage. Association analyses compare the frequencies of the
alleles of single-nucleotide polymorphisms (SNPs) between
cases and controls. With the advances in high-throughput
technologies, sophisticated statistical techniques, and avail-
ability of large collections of well-phenotyped patients, large
genome-wide association studies (GWAS) can compare the
frequencies of hundreds of thousands of SNPs in cases and
controls. GWAS have, to date, been successfully used to find
risk variants in large cohorts of patients with diabetes,
Crohn’s disease (Wellcome Trust Case Control Consortium,
2007), and many other disorders with complex inheritance.
In the past 2 years, genome-wide case–control studies (Capon
et al., 2007; Cargill et al., 2007) and two confirmation
analyses (Smith et al., 2007; Nair et al., 2008) of psoriasis
populations have yielded two candidate loci at IL12B and
IL23R. These candidates offer the promise of clinical
relevance as their gene products have very recently been
considered to have key roles in psoriasis pathophysiology. In
addition, other cytokine genes, IL13 and IL15, have been
identified as harboring variants that associate with psoriasis.
What follows is a review of the recently discovered risk
variants in genes encoding cytokines or their receptors and
their potential relevance to the pathogenesis of psoriasis.
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IL12B VARIANTS AND PSORIASIS RISK
The first large-scale genome-wide case–control association
study of psoriasis that yielded an association between
psoriasis and cytokines and cytokine receptors relevant to
the pathophysiology of psoriasis was reported by Cargill et al.
(2007). This study was carried out by genotyping 467 well-
characterized psoriasis patient from our registry (the Utah
Psoriasis Initiative) and 500 controls for 25,215 gene-centric
SNPs using a disease-phenotype pooling strategy, a method
that essentially screens for associated polymorphisms while
conserving DNA. Polymorphisms that associated with psor-
iasis were evaluated in a second sample set, and those that
maintained their significance were then individually geno-
typed.
The screening phase of this study revealed a highly
significant association of rs3212227 (1188A4C) with psor-
iasis. The presence of the common (A) allele confers risk of
psoriasis with an odds ratio (OR) of 1.59 in the discovery
cohort (confidence interval 1.24–2.04, allelic P-value of
1.89 104) and an OR of 1.81 in the replication cohort
(confidence interval 1.42–2.28) (Table 1). This polymorphism,
located in the 30-untranslated region of IL12B, was first
described in 2000, but early studies did not detect significant
association in patient cohorts of rheumatoid arthritis, multiple
sclerosis, or large granular lymphocyte leukemia with or
without arthritis (Hall et al., 2000). In 2002, a Japanese group
reported an increased frequency of the common (A) allele of
rs3212227 in psoriasis patients but replication in an indepen-
dent sample was never performed (Tsunemi et al., 2002).
Further sequencing and tagSNP analysis of IL12B also
yielded a risk SNP B60 kb upstream of IL12B, rs6887695
(G4C). Again, the common (G) allele conferred risk in the
discovery and two replication cohorts. When considered
together, the two IL12B risk SNPs (A-G) form a psoriasis-
associated haplotype; individuals homozygous for the risk
alleles at both SNPs have a combined OR of 1.40
(Pcombined¼8.11109) for having psoriasis.
Since publication of the Cargill paper, three other studies
have confirmed the association of IL12B SNPs with psoriasis.
Risk alleles of rs3212227 and rs6887695 were both shown to
confer risk for psoriasis in a UK data set of early onset
psoriasis (Smith et al., 2007) and in a case–control and family
based study performed with US and German patients (Nair
et al., 2008). Another study which confirmed association with
rs3212227 also identified an additional SNP upstream of
IL12B, rs10045431, that was not seen in the Cargill study
Table 1. Summary of genotype frequencies, minor allele frequencies, and odds ratios for IL12B SNP rs3212227
Genotype frequency Minor allele frequency
Odds ratio (for common allele
Genotype Patients Controls Patients Controls conferring risk) (confidence interval)
Cargill AA 0.736 0.630
Discovery1 AC 0.242 0.322 0.143 0.209 1.59 (1.24–2.04)
CC 0.021 0.047
Cargill AA 0.750 0.603
Replication1 AC 0.226 0.348 0.137 0.223 1.81 (1.42–2.28)
CC 0.024 0.049
Smith UK2 AA 0.718 0.647
AC 0.256 0.316 0.154 0.194 1.33 (1.11–1.57)
CC 0.026 0.036
Nair US3 AA 0.734 0.594
AC 0.244 0.346 0.145 0.221 1.67 (1.45–1.92)
CC 0.023 0.044
Nair Kiel3 AA 0.730 0.651
AC 0.254 0.316 0.144 0.191 1.41 (1.11–1.50)
CC 0.017 0.033
Capon UK AA NA NA
Discovery4 AC NA NA 0.150 0.180 1.24 (0.99–1.56)
CC NA NA
Capon UK AA NA NA
Replication4 AC NA NA 0.160 0.200 1.31 (1.11–1.55)
CC NA NA
NA, not applicable.
1Cargill et al. (2007).
2Smith et al. (2007).
3Nair et al. (2008).
4Capon et al. (2007).
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(Capon et al., 2007). In all three studies, the common allele is
more frequent in individuals with psoriasis (the minor allele is
protective). A summary of the genotype and allele frequen-
cies for rs3212227 (with ORs performed in the context of the
common allele conferring ‘‘risk’’) from these studies is
presented in Table 1, which illustrates a modest, yet
consistent, effect of this common variant.
IL23R VARIANTS AND PSORIASIS RISK
The discovery of the association of IL12B with psoriasis
prompted a thorough search of other risk variants within the
IL-12/23 receptor–ligand pathway that associate with psor-
iasis. This led to the discovery of and report by Cargill et al.
of two psoriasis-associated polymorphisms within the
gene encoding one subunit of the IL-23 receptor, IL23R.
Genotyping and haplotype analysis of SNPs within IL23R
yielded two additional SNPs, rs7530511 and rs11209026 that
also conferred risk of psoriasis. Of note, the rs11209026
polymorphism is a nonsynonymous SNP that results in an Arg
to Gln substitution (Arg381Gln, or Q381R) that had recently
been found to associate risk of Crohn’s disease (Duerr et al.,
2006). Both rs7530511 and rs11209026 have been replicated
in the aforementioned UK (Smith et al., 2007) and US and
German populations (Nair et al., 2008) and rs11209026 was
also significant in the Capon study. A summary of the
genotype and allele frequencies for rs11209026 (with ORs
performed in the context of the minor allele conferring
protection) is presented in Table 2, which again demonstrates
a consistently modest effect.
ROLE OF IL-12 AND IL-23 IN PSORIASIS
In recent years the roles of cytokines IL-12 and IL-23 in
psoriasis have become increasingly more clear (Fitch et al.,
2007). IL-23 and IL-12 are heterodimeric members of the IL-
12 cytokine family. They are structurally related in that they
share the p40 subunit; IL-12 is formed by the p40 and p35
subunits; IL-23 is formed by the p19 and p40 subunits. IL-12
is known to promote the differentiation of naı¨ve T cells (Th0)
into Th1 lymphocytes, which in turn produce IFN-g and IL-2.
Until recently the ‘‘Th1’’ paradigm was considered central to
the development of psoriasis. However, mounting evidence
suggests that IL-23 may have a more critical role than IL-12 in
the development of psoriasis. Both p40 and p19 mRNA
levels are increased in lesional psoriatic skin, whereas p35 is
not (Lee et al., 2004). In the presence of IL-6 and transforming
growth factor-b, Th0 cells can differentiate into a population
Table 2. Summary of genotype frequencies, minor allele frequencies, and odds ratios for IL23R SNP rs11209026
Genotype frequency Minor allele frequency
Odds ratio (for minor allele
Study population Genotype Patients Controls Patients Controls conferring protection) (confidence interval)
Cargill GG NA NA
Discovery1 GA NA NA 0.044 0.060 0.73 (0.406–1.299)
AA NA NA
Cargill GG NA NA
Replication1 GA NA NA 0.051 0.077 0.64 (0.360–1.077)
AA NA NA
Smith UK2 GG 0.926 0.883
GA 0.074 0.117 0.037 0.060 0.62 (0.446–0.848)
AA 0.000 0.000
Nair US3 GG 0.894 0.867
GA 0.103 0.129 0.053 0.066 0.78 (0.573–1.070)
AA 0.003 0.004
Nair Kiel3 GG 0.914 0.856
GA 0.086 0.137 0.043 0.072 0.56 (0.318–0.986)
AA 0.000 0.006
Capon UK GG NA NA
Discovery4 GA NA NA 0.022 0.072 0.29 (0.158–0.545)
AA NA NA
Capon UK GG NA NA
Replication4 GA NA NA 0.045 0.069 0.63 (0.430–0.925)
AA NA NA
NA, not applicable.
1Cargill et al. (2007).
2Smith et al. (2007).
3Nair et al. (2008).
4Capon et al. (2007).
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of mature T cells distinct from Th1 and Th2, known as
Th17 cells. Th17 cells uniquely express the IL-23 receptor,
made up of two subunits, IL23R and IL12Rb1. In the presence
of IL-23, Th17 cells produce Th17 cytokines, including
IL-17A, IL-17F, IL-6, tumor-necrosis factor (TNF)-a, and
IL-22, which drive downstream events that sustain psoriatic
plaques. Recent data also suggest that etanercept, a TNF-a,
receptor–Ig fusion protein, may inhibit Th17 cytokine
production by dendritic cells within the first 2 weeks of
therapy, whereas Th1-mediated IFN-g production diminishes
much later, supporting a more upstream role of the Th17
cytokines (Zaba et al., 2007). Last, neutralization of p40
with a human mAb leads to marked clinical improvement
of psoriasis plaques, further implicating IL-23 and IL-12
as having an important role in psoriasis (Kauffman et al.,
2004; Krueger et al., 2007). To date, the risk variants in
IL12B and IL23R have not been directly linked to the
expression of IL-12, IL-23, or other key cytokines playing a
role in psoriasis. Figure 1 summarizes the chromosomal
location of the risk SNPs at IL12B and IL23R, the subunits that
may be affected by these variants, and the Th1 and Th17
cytokines that could be modulated by altered expression of
IL-12 or IL-23.
IL23R VARIANTS AND INFLAMMATORY BOWEL DISEASE
Polymorphisms in IL23R have also been found to associate
with risk of inflammatory bowel disease (IBD) and have
been replicated in multiple studies. The same SNP that
associates with psoriasis, rs11209026, was reported initially
in a Crohn’s disease case–control study (Duerr et al.,
2006). Interestingly, this study did not identify the association
of Crohn’s disease with the IL12B risk variants. The rs11209026
polymorphism and others in IL23R have subsequently been
seen in the Wellcome Trust Case–Control Consortium (2007)
GWAS of 14,000 cases and 3,000 controls, and numerous
other GWAS of adult Crohn’s disease (Libioulle et al., 2007;
Parkes et al., 2007; Raelson et al., 2007; Rioux et al., 2007),
UC (Buning et al., 2007), and pediatric IBD (Baldassano et al.,
2007; Van Limbergen et al., 2007).
Like psoriasis, IBD is considered an immune-mediated
multifactorial and polygenic disorder. These two conditions
frequently overlap. Patients with Crohn’s disease have a
fivefold risk of developing psoriasis (Lee et al., 1990) and
anti-TNF-a therapies have efficacy in both disorders. Crohn’s
disease was considered primarily a Th1-mediated disorder
until the Th17 pathway emerged, and IL-23, not IL-12, was
shown to mediate colitis following intestinal bacterial
infection in a mouse model (Hue et al., 2006; Uhlig et al.,
2006). Furthermore, a mAb to IL-23p19 has been shown to
treat and prevent chronic colitis in a mouse model of IBD
(Elson et al., 2007). Although risk variants within IL23R have
an unknown impact on the causation of IBD, a recent study
has demonstrated that carriers of the IL23R risk variants have
significantly higher serum levels of the Th17 cytokine, IL-22,
and greater disease activity scores than the IL23R protective
variant carriers (Schmechel et al., 2008). Thus, more than just
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Figure 1. IL12B and IL23R SNPs. The IL12B SNPs that associate with psoriasis include rs3212227, which resides within the 30-UTR region of IL12B, and
rs6887695, which is B60 kb upstream of IL12B, on chromosome 5q33. The IL23R SNPs that associate with psoriasis include rs11209026 and rs7530511 on
chromosome 1p31.3. IL12B encodes p40, the subunit shared by both IL-12 and IL-23. IL23R encodes one of the two IL-23 receptor subunits. When bound to its
cell-surface receptors, IL-12 promotes the differentiation of naı¨ve Th0 cells into Th1 cells, which in turn produce IFNg and IL-2. In the setting of IL-6 and TGF-b,
IL-23 promotes the differentiation of naı¨ve Th0 cells into Th17 cells, which secrete IL-17A, IL-17F, IL-6, TNF-a, and IL-22. The role of the IL12B and IL23R
polymorphisms in the expression of IL-12, the IL-23 receptor, and their impact on psoriasis pathophysiology remains unknown (adapted courtesy of Centocor,
2008).
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IL13 AND PSORIASIS RISK
Another gene of interest that appeared in the preliminary
results of the Cargill genome-wide scan was IL13, the gene
that codes for IL-13 that resides within the chromosome 5q31
cytokine cluster. IL-13, like IL-4 and IL-10, is secreted by Th2
cells, propagating the allergic inflammatory response seen in
asthma, allergy, helminthic responses, and atopic dermatitis.
Given its immunoregulatory role, the same multitiered
approach used to identify IL12B and IL23R was used to
identify association of psoriasis with three SNPs in IL13:
rs1800925, rs20541, and rs848 (Chang et al., 2008). Like
the IL12B and IL23R SNPs, the common alleles confer a
modest degree of risk, with the risk haplotype CCG conferring
the most risk with a combined OR of 1.27
(Pcombined¼ 1.88104).
The role of IL-13 in psoriasis is yet to be elucidated. IL-13
and the closely related cytokine, IL-4, bind to and send
signals through receptors composed of combinations of four
receptor subunits, IL-4Ra1, IL-13Ra1, IL-13Ra2, and a
common g chain. Although IL-13 and IL-4 could not be
detected in the skin of psoriasis or healthy controls by
RT–PCR or immunohistochemical techniques in two different
studies (Van der Ploeg et al., 1997; Cancino-Diaz et al.,
2002), both IL-13Ra1 and IL-4Ra1 mRNA have been shown
to be overexpressed in lesional and nonlesional skin
(Cancino-Diaz et al., 2002). When added to primary
keratinocyte cultures, IL-13 has been shown to increase
IL-6 (Derocq et al., 1994; Wongpiyabovorn et al., 2003), an
important cytokine in the early development of Th17 cells.
Although still speculative at this time, IL-13 be important in
the dysregulation of the innate and adaptive immune
response that leads to psoriasis.
IL15 AND PSORIASIS RISK
IL-15 is also a cytokine of interest in both the pathogenesis
and genetic susceptibility of psoriasis, as recently reviewed
(Elder, 2007). IL-15 and its receptor IL-15Ra are expressed by
keratinocytes (McInnes and Gracie, 2004), and IL-15 is known
to be overexpressed in lesional psoriatic epidermis (Ruckert
et al., 2000). IL-15 upregulates many proinflammatory
cytokines, including TNF-a, IFN-g, macrophage inflammatory
protein-1a and -1b, IL-1b, and IL-10 (Fehniger and Caligiuri,
2001), and activates human neutrophils (Girard et al., 1996).
IL-15 also stimulates production of IL-17 by T lymphocytes
(Hoeve et al., 2006). Furthermore, antibodies targeting IL-15
bound to its receptor led to reduction of psoriasiform lesions
on a xenograft mouse model (Villadsen et al., 2003).
IL15 resides on chromosome 4q28–31, within the PSORS9
psoriasis susceptibility locus found originally by linkage
analysis (Zhang et al., 2002; Sagoo et al., 2004). A recent
case–control analysis of SNPs in the region identified a highly
significant association of four IL15 SNPs, the most significant
being g.96516A-T in the 30-untranslated region region, with
an ORgenotypic of 1.86 (P¼4 107) (Zhang et al., 2007).
Further investigation of transcriptional activity using a
luciferase reporter assay suggested that the risk haplotypes
were associated with higher expression activity, lending
support to a functional role of these risk variants.
MULTILOCUS MODELS OF GENETIC SUSCEPTIBILITY
A great deal of interest now lies in determining if these risk
variants interact or synergize to increase psoriasis suscept-
ibility. Nair et al. (2008) were unable to detect evidence of
epistasis between HLA-Cw6 and the risk variants in IL12B
and IL23R in a two-locus logistic regression model, but
asserted that the term ‘‘epistasis’’ is not well defined
biologically or statistically. We also have demonstrated lack
of any additive or synergistic effect in logistic regression and
case–control analyses (Tables 3–5). Table 3 shows the
case–control analysis with HLA-Cw*0602 in our population
(OR 4.0) (Table 3). The logistic regression analysis, shown in
Table 4, reveals a higher OR for individuals carrying both
Cw*0602 and the IL12B AA (risk) genotype (OR¼6.17), but
did not reveal any evidence of interaction (w2¼ 1.0, P¼0.32
when compared to those carrying neither risk allele),
suggesting that the effects of HLA-Cw6 and IL12B are
independent. Analysis of HLA-Cw*0602þ cases and con-
trols show that the additional presence of the IL12B risk
genotype does not significantly increase risk of psoriasis
(OR¼1.23, P¼ 0.49) (Table 5). However, in HLA-
Cw*0602 cases and controls, presence of the minor allele
does is associated with reduced risk, suggesting that the
minor allele of rs3212227 may confer additional protection.
We conclude that presence of HLA-Cw*0602 still confers the
highest risk of psoriasis, and the effects of the IL12, IL23R,
and IL13 polymorphisms are quite modest as would be
expected for a common disease variant (Bodmer and Bonilla,
2008). To date, there are no statistical or biological models
that suggest epistasis, but analyses of risk between the
highest- and lowest-risk genotype classes in both the Chang
and Nair studies suggest that obtaining a multilocus genotype
may have prognostic utility in the future (Chang et al., 2008;
Nair et al., 2008). Discovering epistatic interactions in large
data sets will present a significant challenge, given the
Table 3. Psoriasis cases and controls with (+) or
without () Cw*0602
Cw*0602+ Cw*0602 OR (CI)
Cases 209 288 4.01 (2.93–5.48)
Controls 69 381
Table 4. Logistic regression in psoriasis cases and
controls for presence (+) or absence () of HLA-
Cw*0602 and IL12B rs3212227 risk genotype AA
Cw*0602 rs3212227 AA OR (CI) P-value
  1.0 (reference)
 + 1.74 (1.25–2.44) 0.001
+  5.01 (2.85–8.82) o0.0001
+ + 6.17 (4.01–9.49) o0.0001
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computational complexity of analyzing all possible combina-
tions of SNPs, and some authors have suggested that
examining protein–protein interaction will facilitate gene
interaction discoveries (Pattin and Moore, 2008).
PERSPECTIVE
The identification of genetic variations in or near genes
encoding cytokines and cytokine receptors with functional
relevance to psoriasis pathogenesis provides compelling
evidence that GWA is a powerful tool in finding common
genetic variants. Replication of the risk variants in different
populations with very similar ORs also supports the validity of
the association. These findings also harmonize with previous
assertions by psoriasis genetics researchers that several psoriasis
genes exist and are scattered throughout the genome, and that
some of these genes may be involved in a variety of other
inflammatory or immune-mediated diseases other than psor-
iasis (Tarlow et al., 1997; Elder et al., 2001). It is quite possible
that many more common variants exist and contribute to
psoriasis risk. For this reason, collaborative efforts to pool larger
cohorts of cases such as Genetics Association Information
Network (Manolio et al., 2007), which will yield genotypes on
over 400,000 SNPs inB1,400 cases andB1,400 controls, are
underway. Meta-analyses and replication efforts with addi-
tional patient cohorts are expected to yield important new
variants with modest relative risk that have been missed in
studies with smaller sample sizes.
Although GWAS have improved our ability to identify new
genetic variants that associate with psoriasis, other technol-
ogies will be likely be needed to find other important variants
missed by GWAS. Although large studies such as Genetics
Association Information Network have increasingly dense
SNP platforms, GWAS will not be useful in finding
individually rare variants that may be associated with much
higher risks of disease, with particular relevance to psoriasis
in the familial setting. Genome-wide association also does
not allow for assessment of genomic copy number, although
the latest platforms now include specific copy number variant
probes. Copy number variation in the 8p23.1 b-defensin
cluster was recently associated with risk of psoriasis, but this
locus was not identified on previous GWAS (Hollox et al.,
2008).
Ultimately, it will be necessary to translate the information
gained from the study of genetic susceptibility to psoriasis to
the pathogenesis of psoriasis. Genome-wide studies will
likely provide a large number of candidates that will need to
be tested for their functional relevance and for their potential
genetic interactions. Studies are needed to link the presence
of cytokine polymorphisms with molecular events, such as
variations in transcription and translation, in patients with
psoriasis and other immune-mediated disorders. It is our hope
that risk variants can be linked to disease expression, such as
development of psoriatic arthritis or response to therapy,
providing useful prognostic information in the clinic.
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